Genmab A/S (NASDAQ:GMAB) Receives $45.20 Consensus Price Target from Analysts

Shares of Genmab A/S (NASDAQ:GMAB) have earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $45.20.

Several analysts recently commented on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Redburn Atlantic initiated coverage on Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating on the stock. Truist Financial reduced their price objective on Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, September 9th. Morgan Stanley reissued an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genmab A/S in a report on Tuesday, August 20th.

Genmab A/S Price Performance

Genmab A/S stock opened at $21.16 on Monday. Genmab A/S has a 52-week low of $20.34 and a 52-week high of $32.88. The firm has a market capitalization of $14.00 billion, a P/E ratio of 20.54, a P/E/G ratio of 0.65 and a beta of 0.99. The stock has a fifty day moving average price of $22.83 and a two-hundred day moving average price of $25.72.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The firm had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. During the same quarter in the prior year, the business earned $0.47 earnings per share. On average, equities research analysts predict that Genmab A/S will post 1.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Large investors have recently modified their holdings of the business. Legacy Wealth Asset Management LLC boosted its stake in Genmab A/S by 1.1% during the third quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company’s stock valued at $1,097,000 after buying an additional 471 shares during the period. Benjamin F. Edwards & Company Inc. raised its stake in shares of Genmab A/S by 7.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after acquiring an additional 478 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock valued at $28,000 after purchasing an additional 544 shares in the last quarter. Eagle Asset Management Inc. grew its holdings in shares of Genmab A/S by 10.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock valued at $285,000 after purchasing an additional 1,121 shares during the last quarter. Finally, Rhumbline Advisers raised its position in Genmab A/S by 7.1% in the 2nd quarter. Rhumbline Advisers now owns 18,694 shares of the company’s stock worth $470,000 after purchasing an additional 1,236 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.